Company · ARGX
argenx
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
2
2 still marketed
Novel approvals
1
Approvals since 2021
10
Originals and new uses
Phase 3 trials
30
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Vyvgart Hytrulo new use Priority reviewOrphanMay 8, 2026
- Vyvgart new use Priority reviewOrphanMay 8, 2026
- Vyvgart Hytrulo new use OrphanOct 17, 2025
- Vyvgart new use OrphanOct 17, 2025
- Vyvgart Hytrulo new use OrphanApr 10, 2025
- Vyvgart Hytrulo new use OrphanAug 8, 2024
- Vyvgart new use OrphanAug 8, 2024
- Vyvgart Hytrulo new use Priority reviewOrphanJun 21, 2024
- Vyvgart Hytrulo approved Priority reviewOrphanJun 20, 2023
- Vyvgart approved NovelOrphanDec 17, 2021
Drugs in development (3)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
Recruiting Phase 3 trials
Largest first.
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.Pivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07596849 · 230 participants (planned) · Start Jun 10, 2026 · Primary completion Jun 2028
Drug: efgartigimod PH20 SC · For: Graves Disease
Sites: Aalst, Belgium; Ghent, Belgium; Pazardzhik, Bulgaria · 51 sites in all
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' DiseasePivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07570316 · 230 participants (planned) · Start Jun 10, 2026 · Primary completion Jun 2028
Drug: Efgartigimod PH20 SC · For: Graves' Disease; Graves Disease
Sites: Carlsbad, California; Orange, California; Pasadena, California · 35 sites in all
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT06920004 · 218 participants (planned) · Start Aug 22, 2025 · Primary completion Sep 2027
Drug: empasiprubart; IVIg · For: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Birmingham, Alabama; Tucson, Arizona; Rancho Mirage, California · 109 sites in all
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07091630 · 160 participants (planned) · Start Sep 16, 2025 · Primary completion Oct 7, 2027
Drug: Empasiprubart IV · For: Chronic Inflammatory Demyelinating Polyneuropathy; CIDP; Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Sites: Birmingham, Alabama; Tucson, Arizona; Rancho Mirage, California · 95 sites in all
- A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune ThrombocytopeniaPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT06544499 · 69 participants (planned) · Start Oct 18, 2024 · Primary completion Jun 2028
Drug: Efgartigimod IV · For: Primary Immune Thrombocytopenia (ITP)
Sites: Phoenix, Arizona; Los Angeles, California; Oceanside, California · 94 sites in all
- A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07194850 · 24 participants (planned) · Start Oct 20, 2025 · Primary completion Oct 2028
Drug: Efgartigimod IV · For: Immune Thrombocytopenia (ITP); ITP - Immune Thrombocytopenia; ITP and 4 more
Sites: Bordeaux, France; La Tronche, France; Vandœuvre-lès-Nancy, France · 28 sites in all
- A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia GravisPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT06392386 · 12 participants (planned) · Start Jun 28, 2024 · Primary completion Sep 2027
Drug: Efgartigimod PH20 SC · For: Generalized Myasthenia Gravis
Sites: Charlotte, North Carolina; Denton, Texas; Charlottesville, Virginia · 22 sites in all
Marketed drugs (2)
Newest FDA action first.
- Vyvgart Hytrulo Efgartigimod Alfa and Hyaluronidase-Qvfc · 2023
- Vyvgart Efgartigimod Alfa · 2021
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.